Table 5.
Distribution of steatosis grades by chronic liver disease etiology
| Etiology | Steatosis grades among patients, n (%) | Total, n (%) | |||
|---|---|---|---|---|---|
| S0 | S1 | S2 | S3 | ||
| NAFLD | 417 (8.7) | 356 (7.5) | 775 (16.3) | 3220 (67.5) | 4768 (100.0) |
| HCV | 370 (52.3) | 89 (12.6) | 123 (17.4) | 125 (17.7) | 707 (100.0) |
| HBV | 1457 (45.6) | 505 (15.8) | 500 (15.7) | 732 (22.9) | 3194 (100.0) |
| Metabolic liver diseases | 19 (46.3) | 7 (17.1) | 6 (14.6) | 9 (22.0) | 41 (100.0) |
| DILI | 42 (24.9) | 15 (8.9) | 28 (16.6) | 84 (49.7) | 169 (100.0) |
| PSC/PBC | 48 (51.1) | 15 (16.0) | 17 (18.1) | 14 (14.9) | 94 (100.0) |
| ALD | 46 (16.7) | 30 (10.9) | 57 (20.7) | 142 (51.6) | 275 (100.0) |
| AIH | 54 (55.7) | 15 (15.5) | 10 (10.3) | 18 (18.6) | 97 (100.0) |
| Total | 2453 (26.2) | 1032 (11.0) | 1516 (16.2) | 4344 (46.6) | 9345 (100.0) |
NAFLD: Nonalcoholic fatty liver disease; HCV: Hepatitis C virus; HBV: Hepatitis B virus; DILI: Drug-induced liver injury; PSC/PBC: Primary sclerosing cholangitis and primary biliary cirrhosis; ALD: Alcoholic liver disease; AIH: Autoimmune hepatitis.